

Table II. Univariate and multivariate analyses to identify prognostic factors in HER2-positive GC patients who underwent chemotherapy.

	Univariate analysis		Multivariate analysis	
	Hazard ratio	<i>p</i> -Value	Hazard ratio	<i>p</i> -Value
Sex (male)	0.35	0.26		
Age (>75)	1.58	0.48		
HER2 score 3	0.89	0.86		
Tumor type 3 or 4	1.58	0.46		
Tumor location (U)	1.89	0.34		
Tumor differentiation (por-sig)	1.62	0.56		
Stage IV ^a (before the treatment)	1.47	0.55		
Postoperative recurrence (+)	0.60	0.42		
Gastrectomy (+)	0.28	0.06	0.52	0.36
CEA (>5 ng/ml)	0.66	0.49		
CA19-9 (>37 U/ml)	0.94	0.92		
CR or PR to chemotherapy with trastuzumab	0.08	0.0007	0.12	0.008
FGFR2 positive in IHC	4.55	0.03	1.76	0.55

^aThe 8th edition of the International Union Against Cancer (UICC) tumor-node-metastasis (TNM) classification (17). CEA, Carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9.